Accept Cookies?
Provided by OpenGlobal E-commerce

Please wait while your page loads ...

Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia

 

DUBLIN, IRELAND -- (Marketwired) -- 04/10/15 -- Horizon Pharma plc (NASDAQ: HZNP), a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs, today announced the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ACTIMMUNE® (interferon gamma-1b) in the treatment of Friedreich's ataxia (FA), a degenerative neuro-muscular disorder.

Read more: Horizon Pharma plc Receives FDA Fast Track Designation for ACTIMMUNE(R) in the Treatment of Friedreich's Ataxia

Related Link:

Wall Street Journal

SHARE

FacebookTwitterLinkedInYoutube
Science C.jpg

News & Press Archives

Site Map     Privacy Policy     Service Terms     Log-in     Contact     Charity Navigator